Alessandro Berni

Alessandro Berni

Auto-generated profile, based on publicly available information

Alessandro Berni

Department of Ophthalmology, Bascom Palmer Eye Institute (O.S.E.M., A.B., J.K., M.S., G.H., S.B., O.T., M.D.N., R.O.B., G.G., P.J.R.), University of Miami Miller School of Medicine, Miami, Florida, USA; Department of Ophthalmology (A.B.), IRCCS San Raffaele Scientific Institute, Milan, Italy

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2023 in European Journal of Ophthalmology
Verified
Journal Article
Closed access
CBCostanza Barresi
Costanza Barresi
Jay ChhablaniJay Chhablani
Jay Chhablani
Rosa Dolz-Marco PhDRosa Dolz-Marco PhD
Rosa Dolz-Marco PhD
RGRobero Gallego-Pinazo
Robero Gallego-Pinazo
ABAlessandro Berni
Alessandro Berni
Enrico BorrelliEnrico Borrelli
Enrico Borrelli
Age-related macular degeneration (AMD) is a complex and multifactorial disease characterized by the damage of the unit comprised of the photoreceptors, retinal pigment epithelium (RPE), Bruch's membrane, and choriocapillaris. Although the outer retina appears to be mainly affected in this disorder, several evidences exhibit that also the inner retina may be impaired. In this review we will provide a description of the prominent histologic and imaging findings suggesting an inner retinal loss in these eyes. In details, structural optical coherence tomography (OCT) technology proved either the inner and outer retina is impacted by AMD and that these two impairments are associated. Therefore, the purpose of this review is to provide a description of the role of neurodegeneration in AMD in order to better understand the relationship between neuronal loss and the outer retinal damage in this disease.

27 March 2023 in European Journal of Ophthalmology
Verified
Journal Article
Open access
LBLorenzo Bianco
Lorenzo Bianco
AAAlessandro Arrigo
Alessandro Arrigo
AAAlessio Antropoli
Alessio Antropoli
ABAlessandro Berni
Alessandro Berni
ASAndrea Saladino
Andrea Saladino
MPMaurizio Battaglia Parodi
Maurizio Battaglia Parodi
Best Vitelliform Macular Dystrophy (BVMD) is a dominantly inherited retinal disease caused by dominant variants in the BEST1 gene. The original classification of BVMD is based on biomicroscopy and color fundus photography (CFP); however, advancements in retinal imaging provided unique structural, vascular, and functional data and novel insights on disease pathogenesis. Quantitative fundus autofluorescence studies informed us that lipofuscin accumulation, the hallmark of BVMD, is unlikely to be a primary effect of the genetic defect. It could be due to a lack of apposition between photoreceptors and retinal pigment epithelium in the macula with subsequent accumulation of shed outer segments over time. Optical Coherence Tomography (OCT) and adaptive optics imaging revealed that vitelliform lesions are characterized by progressive changes in the cone mosaic corresponding to a thinning of the outer nuclear layer and then disruption of the ellipsoid zone, which are associated with a decreased sensitivity and visual acuity. Therefore, an OCT staging system based on lesion composition, thus reflecting disease evolution, has been recently developed. Lastly, the emerging role of OCT Angiography proved a greater prevalence of macular neovascularization, the majority of which are non-exudative and develop in late disease stages. In conclusion, effective diagnosis, staging, and clinical management of BVMD will likely require a deep understanding of the multimodal imaging features of this disease.

30 October 2022 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
LPLuisa Pierro
Luisa Pierro
LBLorenzo Bianco
Lorenzo Bianco
FBFederico Bertuzzi
Federico Bertuzzi
AAAlessandro Arrigo
Alessandro Arrigo
ASAndrea Saladino
Andrea Saladino
Francesco BandelloFrancesco Bandello
Francesco Bandello

11 November 2022 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
Enrico BorrelliEnrico Borrelli
Enrico Borrelli
ABAlessandro Berni
Alessandro Berni
MCMaria Lucia Cascavilla
Maria Lucia Cascavilla
CBCostanza Barresi
Costanza Barresi
MBMarco Battista
Marco Battista
PBPiero Barboni
Piero Barboni

5 September 2023 in European Journal of Ophthalmology
Verified
Journal Article
Open access
AAAlessio Antropoli
Alessio Antropoli
AAAlessandro Arrigo
Alessandro Arrigo
LPLorenzo Pili
Lorenzo Pili
LBLorenzo Bianco
Lorenzo Bianco
ABAlessandro Berni
Alessandro Berni
MPMaurizio Battaglia Parodi
Maurizio Battaglia Parodi
Pigmented paravenous chorioretinal atrophy (PPCRA) is an uncommon form of chorioretinal atrophy characterized by perivenous aggregations of pigment clumps associated with peripapillary and radial zones of retinal pigment epithelial atrophy that are distributed along the retinal veins. Most patients are asymptomatic, and evidence suggest that PPCRA is slowly progressing. Unless macular involvement is present, the majority of patients usually retain a normal visual function. Our ability to diagnose PPCRA has recently improved thanks to multimodal imaging, especially with the advent of ultra-widefield (UWF) imaging. Blood tests and functional and genetic testing can help with the correct differential diagnosis of pseudo-PPCRA or other disorders with similar characteristics. Although the cause of PPCRA is unknown, it is possible that it has a genetic basis. In this review we provide a summary of the multimodal imaging characteristics of PPCRA, and discuss its possible pathogenesis, based on the genes that have been associated with this disease.

27 April 2023 in European Journal of Ophthalmology
Verified
Journal Article
Open access
ABAlessandro Berni
Alessandro Berni
AAAlessandro Arrigo
Alessandro Arrigo
LBLorenzo Bianco
Lorenzo Bianco
AAAlessio Antropoli
Alessio Antropoli
ASAndrea Saladino
Andrea Saladino
MPMaurizio Battaglia Parodi
Maurizio Battaglia Parodi
Retinitis pigmentosa (RP) is a group of inherited rod-cone dystrophies, noted for a high genotypical and phenotypical heterogeneity. Traditionally, VA, visual field, and electroretinography have been used to assess RP progression. However, visual acuity and visual field tests are essentially subjective and, especially in the late stages of the disease, are unable to confidently reveal minor progression. Therefore, there is a need for novel examination modalities that rely on quantitative, structural measurements. In this regard, several non-invasive imaging techniques have been studied, including spectral-domain optical coherence tomography, optical coherence tomography angiography, and fundus autofluorescence. By correlating surrogate biomarkers with functional measurements of the disease, these techniques may be able to develop reliable outcome meters that can be used to gain a deeper understanding of the underlying causes of the disease and to assess the effectiveness of therapy even before an actual loss of vision occurs. In this review, we will summarize the recent imaging findings and biomarkers that have been identified in RP patients. Our goal is to provide information that can promptly aid in selecting patients for clinical trials and new gene therapies, monitoring the disease progression, and evaluating treatment outcomes.